# BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload

Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while minimizing systemic toxicity. The RTNova platform aims to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies.

 To view the full press release, visit: https://ibn.fm/4TR7U

 About Calidi Biotherapeutics

 Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

 For more information, please visit www.calidibio.com

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-calidi-biotherapeutics-inc-nyse-american-cldi-advances-rtnova-platform-with-il15-superagonist-payload/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/calidi-biotherapeutics-selects-il15-superagonist-for-antitumor-virotherapy-platform/e16eb2e8e848b0a90d042a0346acd029) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1ka05ys/calidi_biotherapeutics_selects_il15_superagonist/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/28/yarn2zlv.webp)